| Summary: | Susanne Gardner,1 Peter Barry,2 Luis Cordovés3 1European Society of Cataract and Refractive Surgery, Dublin, Ireland; 2Ophthalmic Surgery, St Vincents University Hospitals Group, Dublin, Ireland; 3Retina and Vitreous Section, Ophthalmology Service, Hospital Universitario de Canarias, SpainWe read with concern the findings of toxic anterior segment syndrome in patients receiving intracameral injection of cefuroxime axetil, as described in the report by Çakir et al1 in the March 2015 issue of Clinical Ophthalmology. Notably, the authors state that the form of cefuroxime used to extemporaneously compound cefuroxime for intracameral injection was cefuroxime axetil and that 17 cases of toxic anterior segment syndrome ensued. With over one million doses of intracameral cefuroxime administered to date, and with extensive clinical experience,2 the unfortunate scenario described by the authors has not been realized elsewhere.View original article by Çakır et al
|
|---|
